AN EX-VIVO COMBINATION DRUG SENSITIVITY PLATFORM FOR PREDICTING SENSITIVITY TO FLT3 INHIBITOR-BASED COMBINATION IN ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Sahib, Noor Rashidha Bte Meera
Ying, Jen Wei
Ooi, Melissa
Chee, Yen Lin
Jayalakshmi
Mohamed, Jameelah Bte Sheik
Rashid, Masturah
Chow, Edward K. H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 08期
关键词：
D O I：
10.1158/1538-7445.FCS2023-P09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P09
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An Ex-Vivo Combination Drug Sensitivity Platform for Predicting Sensitivity to FLT3 Inhibitor-Based Combination in Acute Myeloid Leukemia
    Sahib, Noor Rashidha Binte Meera
    Ying, Jen Wei
    Ooi, Melissa
    Chee, Yen Lin
    Rashid, Masturah
    Jayalakshmi, Jayalakshmi
    Chow, Edward K. H.
    [J]. BLOOD, 2022, 140 : 7840 - 7841
  • [2] Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo
    John, Bincy
    Sundaramoorthy, Pasupathi
    Rainbolt, Elizabeth
    Wong, Andrew
    Ward, Zachary
    Avery, Justin
    Todd, Savannah
    Kidder, Shasta
    Gietl, Diana
    Hall, Chassidy
    Harris, David
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [3] Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.
    Rosenberg, Mara
    Fan, Guang
    Watanabe-Smith, Kevin
    Tognon, Cristina
    Druker, Brian J.
    Tyner, Jeffrey
    Loriaux, Marc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
    Mollgard, Lars
    Deneberg, Stefan
    Nahi, Hareth
    Bengtzen, Sofia
    Jonsson-Videsater, Kerstin
    Fioretos, Thoas
    Andersson, Anna
    Paul, Christer
    Lehmann, Soren
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 439 - 448
  • [5] The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
    Lars Möllgård
    Stefan Deneberg
    Hareth Nahi
    Sofia Bengtzen
    Kerstin Jonsson-Videsäter
    Thoas Fioretos
    Anna Andersson
    Christer Paul
    Sören Lehmann
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 62 : 439 - 448
  • [6] Personalized phenotypic ex vivo drug sensitivity platform identifies frequent HDAC inhibitor-based combination sensitivities in T-cell lymphomas.
    Goh, Jasmine Ya Hwee
    De Mel, Sanjay
    Rashid, Masturah
    Jeyasekharan, Anand
    Chow, Edward Kai-Hua
    [J]. CANCER RESEARCH, 2022, 82 (23)
  • [7] BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
    Stone, Richard M.
    [J]. HAEMATOLOGICA, 2021, 106 (04) : 931 - 932
  • [8] Ex vivo drug sensitivity of acute myeloid leukemia by apoptotic drug sensitivity (ADS) assay.
    Bosanquet, AG
    Bavin, P
    Burlton, AR
    Bell, PB
    [J]. BLOOD, 2000, 96 (11) : 123A - 123A
  • [9] CELL CYCLE MODELING OFFERS A PLATFORM TO OPTIMIZE COMBINATION OF CYTARABINE AND FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA
    Elmeliegy, M.
    Haese, J.
    Talati, C.
    Jusko, W.
    Wetzler, M.
    [J]. HAEMATOLOGICA, 2013, 98 : 507 - 508
  • [10] The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
    E Chang
    S Ganguly
    T Rajkhowa
    C D Gocke
    M Levis
    H Konig
    [J]. Leukemia, 2016, 30 : 1025 - 1032
12345